Clinical trials: Diffuse Interstitial Lung Disease
Diffuse Interstitial Lung Disease
Innovation in Endobronchial Sampling
Evaluating an integrated diagnostic work-up of virtual navigation bronchoscopy (VNB), confocal laser endomicroscopy and micro computerized tomography (micro-CT) in the diagnostic path of pulmonary lesions in the non-oncological…
- Trial name
- NCT02380326
- Testing
- Advanced endoscopic imaging modalities
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Post COVID-19 Diffuse Lung Disease
Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia.
- Trial name
- COLDSTER (NCT04657484)
- Testing
- Medium dose prednisolone, Low dose prednisolone
- Where
- India
- Volunteers
- 130 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Systemic Sclerosis
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this…
- Trial name
- NCT07047690
- Testing
- Nemolizumab
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with…
- Trial name
- CONQUEST (NCT06195072)
- Testing
- Amlitelimab, BI 1015550 (Nerandomilast)
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Scleroderma Research Foundation, Inc.
Scleroderma
MRI for Screening and Monitoring Scleroderma ILD
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
- Trial name
- NCT05204355
- Testing
- MRI, Hyperpolarized Xe129, HRCT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Diffuse Parenchymal Lung Diseases
Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases
The purpose of this study is to generate a prospective database of all patients evaluated for diffuse parenchymal lung diseases to provide much needed data on the various disease aetiologies, incidence and prevalence rates…
- Trial name
- NCT01600378
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Interstitial Lung Disease, Scleroderma
Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
- Trial name
- RECITAL (NCT01862926)
- Testing
- Rituximab, Cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Diffuse Parenchymal Lung Disease
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)
The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD).
- Trial name
- NCT04392726
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Diffuse Parenchymal Lung Disease, Pulmonary Hypertension
Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease
The purpose of this study was to investigate the acute effects of sildenafil on diffusion capacity, a commonly performed pulmonary function test, which is used to assess the lungs' gas exchange capability.
- Trial name
- NCT01948518
- Testing
- Oral sildenafil 20 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Scleroderma, Interstitial Lung Disease
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection.
- Trial name
- SLSII (NCT00883129)
- Testing
- Mycophenolate mofetil, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 142 people
- Sponsor
- Michael Roth
Diffuse Parenchymal Lung Disease
The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease
Diffuse Parenchymal Lung Disease(DPLD) is a chronic progressive fibrosis lung disease that with a highly variable clinical process.Krebs von den Lungen-6 (KL-6) is a high-molecular-weight glycoprotein, classified as human MUC1…
- Trial name
- NCT03101397
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Born out of the European Union 7th Framework Programme funded project European IPF Network (eurIPFnet), the European IPF Registry (eurIPFreg) has become Europe's leading database of longitudinal data from IPF patients, including…
- Conditions
- Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases
- Trial name
- eurIPFreg (NCT02951416)
- Testing
- patient registry (observation and biomaterial sampling)
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Andreas Guenther
Scleroderma
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
Assessment of pulmonary fibrosis is currently based on high-resolution CT (HRCT) and pulmonary function tests (PFT) such as forced vital capacity, (FVC) and carbon monoxide diffusion (DLCO).
- Trial name
- IRMSCLERO (NCT03207997)
- Testing
- unenhanced MR sequences
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Diseases
Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD…
- Trial name
- EvER-ILD2 (NCT05596786)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 126 people
- Sponsor
- University Hospital, Tours
Systemic Sclerosis, Scleroderma
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients.
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease
- Trial name
- MYILD (NCT02896205)
- Testing
- Mycophenolate mofetil
- Where
- India
- Volunteers
- 41 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Interstitial Lung Disease
Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies
Diffuse interstitial lung diseases (ILDs) represent a group of rare, heterogeneous disorders of various etiologies, all sharing a common histopathological feature: fibrotic remodeling of the pulmonary parenchyma induced by a…
- Trial name
- INTREPID (NCT06980844)
- Testing
- No intervention: no treatment
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hopital Foch
Interstitial Lung Disease, Scleroderma
Open-label Study With Bosentan in Interstitial Lung Disease
This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.
- Trial name
- BUILD 2 OL (NCT00319033)
- Testing
- bosentan
- Volunteers
- 132 people
- Sponsor
- Actelion
Sarcoidosis
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and The World Association of Sarcoidosis and Other Granulomatous Disorders…
- Trial name
- SARCORT (NCT03265405)
- Testing
- Low dose prednisolone, Medium dose prednisolone
- Where
- India
- Volunteers
- 86 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Diffuse Astrocytoma, Anaplastic Astrocytoma
Pediatric Long-Term Follow-up and Rollover Study
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT03975829
- Testing
- dabrafenib, trametinib
- Where
- 54 sites in United States, Argentina and 17 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals